Study of Capecitabine and Docetaxel in Cancer Patients
Author Information
Author(s): Pronk L C, Vasey P, Sparreboom A, Reigner B, Planting A S Th, Gordon R J, Osterwalder B, Verweij J, Twelves C
Primary Institution: Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, The Netherlands
Hypothesis
The study aims to determine the maximum tolerated dose and side effects of the combination of capecitabine and docetaxel in patients with advanced solid tumors.
Conclusion
The combination of capecitabine and docetaxel was found to be tolerable with manageable side effects.
Supporting Evidence
- Thirty-three patients were treated with capecitabine and docetaxel.
- The dose-limiting toxicity was asthenia grade 2–3.
- Neutropenia grade 3–4 occurred in 68% of courses.
- There were two complete responses and three partial responses in tumor responses.
Takeaway
Doctors tested two cancer drugs together to see how much they could give without making patients too sick, and they found a safe amount that worked well.
Methodology
Patients received capecitabine orally and docetaxel intravenously over a specified treatment schedule to assess side effects and maximum tolerated doses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website